Adaptive Biotechnologies Corporation is rated Hold as MRD segment momentum offset by competitive & valuation concerns. Read ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

"Watch as Trump's White House briefing takes a surprising turn at the podium, leaving viewers puzzled and intrigued. What ...

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for ...

U.S. President Donald Trump unveiled agreements with nine major pharmaceutical companies to lower the prices of medicines sold to the Medicaid program ...

The FDA approved a new 300 mg/2 mL dose of Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of four allergic and ...

Roche CEO predicts higher drug costs in Switzerland due to U.S. government's deals with pharmaceutical companies.

Genentech, a member of the Roche Group, said the U.S. Food and Drug Administration approved its treatment for follicular lymphoma.

Trump on Friday announced what the White House described as the largest set of developments to date under his administration’s push to bring prescription drug prices in the United States in line with ...

LUNSUMIO (mosunetuzumab-axgb) or LUNSUMIO VELO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who ...